Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00797953 · ClinicalTrials.gov registry record · Phase 2
Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina
A Phase 2 study of Angina Pectoris, sponsored by Tasly Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 15
- Study locations
NCT00797953: Completed Phase 2 study of Angina Pectoris, sponsored by Tasly Pharmaceuticals.
NCT00797953 is a Phase 2 study of Angina Pectoris that has completed, run by Tasly Pharmaceuticals. The registered enrollment target is 124 participants, below the 901-participant average among 9 other Angina Pectoris trials with a reported enrollment target (86% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00797953, a Phase 2 study of Angina Pectoris, has completed, sponsored by Tasly Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to determine the anti-angina effect and dose response of T89, a 2-herb botanical drug product, in patients with chronic stable angina pectoris in the United States.
Conditions Studied
Interventions
- DRUG T89
Study Locations (15)
Texas
- East Texas Cardiology - Houston
- Northwest Houston Cardiology - Houston
- Northwest Heart Center - Tomball
California
- Robert M. Karns, A Medical Corporation - Beverly Hills
- Inland Heart Doctors - Corona
Florida
- Sunrise Medical Research - Lauderdale Lakes
- Cardiovascular Research Center of South Florida - Miami
Arizona
- Paradigm Clinical, Inc. - Tucson
Louisiana
- Alexandria Cardiology Clinic - Alexandria
Michigan
- Great Lakes Research Group, Inc - Bay City
New York
- Marc Kozinn Associates - Williamsville
Oklahoma
- Oklahoma Cardiovascular & Hypertension - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2007-02 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
What the finished NCT00797953 record still lists
NCT00797953 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 901-participant average among 9 other Angina Pectoris trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Angina Pectoris appearing as the primary indexed condition, and to 1 intervention - of which T89 is the first listed.
NCT00797953 lists 15 locations in 11 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT00797953 about?
NCT00797953 is a clinical study titled "Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina". The purpose of this study is to determine the anti-angina effect and dose response of T89, a 2-herb botanical drug product, in patients with chronic stable angina pectoris in the United States.
What is the current status of trial NCT00797953?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2007-02. Estimated completion is 2010-01.
What conditions does trial NCT00797953 study?
This clinical trial studies the following conditions: Angina Pectoris.
What interventions are being tested in trial NCT00797953?
The interventions under investigation include: T89 (DRUG).
Who is sponsoring clinical trial NCT00797953?
This trial is sponsored by Tasly Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00797953 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angina Pectoris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00797953's enrollment target sits among peer trials
124 10th of 9 the lowest of 9 other Angina Pectoris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Angina Pectoris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries
RECRUITING · Phase 2
-
Invest-CTO PCI Trial
ACTIVE NOT RECRUITING · NA
-
Comparing TR Band to Statseal in Conjunction With TR Band
COMPLETED · NA
-
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
COMPLETED
-
Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)
COMPLETED
-
Collaborative Cardiac Care Project
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia